Literature DB >> 21450628

Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men.

Takahisa Kondo1, Shigeki Osugi, Keiko Shimokata, Haruo Honjo, Yasuhiro Morita, Kentaro Yamashita, Kengo Maeda, Takashi Muramatsu, Satoshi Shintani, Kunihiro Matsushita, Toyoaki Murohara.   

Abstract

AIM: The association between subjects with metabolic syndrome (MS) who were considered not to require medication by their attending physicians and all-cause mortality, ischemic heart disease (IHD) and cardiovascular disease (CVD) remains unknown and should be clarified. METHODS AND
RESULTS: This is an observational longitudinal cohort study with a median follow-up of 7.5 years performed for 25,471 Japanese men aged 20-61 years who were not on medication. We used a modified definition of MS from the Japanese Society of Internal Medicine and the NCEP ATPIII, both of which employed body mass index instead of waist circumference. MS was associated with increased rates of all-cause death (adjusted hazard ratio (HR): 4.88 [95% confidence interval, 2.96-7.66]), IHD (3.17 [1.06-7.65]), and CVD (2.63 [1.32-4.72]). In contrast, overweight subjects with no component or one component had similar rates to subjects of normal weight. Any combination of the three MS components was associated with significantly greater rates of all-cause mortality (HR: 3.18-11.2) and IHD (HR: 3.17-8.24), whereas blood pressure elevation plus dyslipidaemia was associated with a significantly higher rate of CVD (HR: 3.27). In any endpoint, MS defined by Japanese criteria had higher HRs than defined by NCEP ATP III criteria.
CONCLUSION: Young and middle-aged Japanese men with MS who had been viewed as not needing medication already showed increased rates of all-cause mortality, IHD and CVD. Additionally, the event rate depended on the specific combination of metabolic syndrome components.

Entities:  

Mesh:

Year:  2011        PMID: 21450628     DOI: 10.1177/1741826710389529

Source DB:  PubMed          Journal:  Eur J Cardiovasc Prev Rehabil        ISSN: 1741-8267


  13 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  Metabolic syndrome across Europe: different clusters of risk factors.

Authors:  Angelo Scuteri; Stephane Laurent; Francesco Cucca; John Cockcroft; Pedro Guimaraes Cunha; Leocadio Rodriguez Mañas; Francesco U Mattace Raso; Maria Lorenza Muiesan; Ligita Ryliškytė; Ernst Rietzschel; James Strait; Charalambos Vlachopoulos; Henry Völzke; Edward G Lakatta; Peter M Nilsson
Journal:  Eur J Prev Cardiol       Date:  2014-03-19       Impact factor: 7.804

3.  Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study.

Authors:  Manuel A Gomez-Marcos; Jose I Recio-Rodríguez; Maria C Patino-Alonso; Cristina Agudo-Conde; Leticia Gomez-Sanchez; Emiliano Rodriguez-Sanchez; Marta Gomez-Sanchez; Luis Garcia-Ortiz
Journal:  Cardiovasc Diabetol       Date:  2011-10-14       Impact factor: 9.951

4.  Low intensive lifestyle modification in young adults with metabolic syndrome a community-based interventional study in Taiwan.

Authors:  Yi-Lien Liu; Chia-Wen Lu; Leiyu Shi; Yiing-Mei Liou; Long-Teng Lee; Kuo-Chin Huang
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 5.  Impact of Mediterranean diet on metabolic syndrome, cancer and longevity.

Authors:  Nicola Di Daniele; Annalisa Noce; Maria Francesca Vidiri; Eleonora Moriconi; Giulia Marrone; Margherita Annicchiarico-Petruzzelli; Gabriele D'Urso; Manfredi Tesauro; Valentina Rovella; Antonino De Lorenzo
Journal:  Oncotarget       Date:  2017-01-31

6.  Effects of eplerenone on blood pressure and glucose metabolism in Japanese hypertensives with overweight or obesity.

Authors:  Hisashi Adachi; Tatsuyuki Kakuma; Machiko Kawaguchi; Eita Kumagai; Yoshihiro Fukumoto
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Blood rheology and platelet function in untreated early-stage essential hypertensives complicated with metabolic syndrome.

Authors:  Hiroko Sugimori; Fumihiro Tomoda; Tsutomu Koike; Hiroyuki Kinuno; Hiroko Kurosaki; Toshitaka Masutani; Hiroshi Inoue
Journal:  Int J Hypertens       Date:  2012-04-18       Impact factor: 2.420

8.  Metabolic syndrome, C-reactive protein, and mortality in U.S. Blacks and Whites: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study.

Authors:  Takeki Suzuki; Jenifer Voeks; Neil A Zakai; Nancy Swords Jenny; Todd M Brown; Monika M Safford; Martin LeWinter; George Howard; Mary Cushman
Journal:  Diabetes Care       Date:  2014-05-30       Impact factor: 19.112

9.  The Cohort Study on Prediction of Incidence of All-Cause Mortality by Metabolic Syndrome.

Authors:  Zhixia Li; Xinghua Yang; Jun Yang; Zhirong Yang; Shengfeng Wang; Feng Sun; Siyan Zhan
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240

10.  Influence of Post-disaster Evacuation on Incidence of Metabolic Syndrome.

Authors:  Shigeatsu Hashimoto; Masato Nagai; Shingo Fukuma; Tetsuya Ohira; Mitsuaki Hosoya; Seiji Yasumura; Hiroaki Satoh; Hitoshi Suzuki; Akira Sakai; Akira Ohtsuru; Yukihiko Kawasaki; Atsushi Takahashi; Kotaro Ozasa; Gen Kobashi; Kenji Kamiya; Shunichi Yamashita; Shun-Ichi Fukuhara; Hitoshi Ohto; Masafumi Abe
Journal:  J Atheroscler Thromb       Date:  2016-09-13       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.